seraprognostics.com - רווח החברה לפני מסים, ריבית ופחת SERA

Sera Prognostics (SERA) dominates molecular diagnostics through its exclusive PreTRM test for the prevention of preterm birth. The company's estimated EBITDA reflects profit dynamics, where 0.00 serves as the current parameter value. Analysis accuracy is ensured by costly thermologistics for biomaterials. The stability of the R&D department and the active hiring of sales representatives sustain the business's technological advantage.

This indicator measures net cash flow from operating activities before depreciation and interest, reflecting the business's actual ability to generate internal resources. For Sera Prognostics (SERA), which is currently in the test launch stage, the negative operating profit confirms a reliance on liquidity reserves, turning this chart into a tool for monitoring the burn rate.